A recent study reported that Wnt5a was significantly increased in the serum and myocardium of patients with heart failure and decreased after left ventricular assist device therapy (Abraityte et al., 2017b), implying that Wnt5a may be an ideal molecular target for CHF treatment. This evidence concerns the gene WNT5A and heart failure.